Infants, Career Or Erlotinib

Radical surgery was the initial diagnostic procedure in 3 cases (21.5%) versus endoscopic biopsy in 11 cases (78.5%). Median age for the whole group is 53 years while for the GI involvement group it was 48 years. At a median follow up period of 13 months, the median PFS for the whole group was 79 months while for the GI involvement group it was 25 months; adverse clinicopathological factors(age http://www.selleckchem.com/products/MK-2206.html >60 years, advanced stage, poor performance or elevated LDH) was not statistically different between the 2 groups. Based on univariate analysis, GI involvement was not associated with shorter PFS (p=0.68). Conclusion: According to our data, there is unnecessary high rates of radical surgery in the initial diagnosis of GI DLBCL, possibly related to diagnostic confusion with other GI malignancies; proper preoperative assessment and multidisciplinary discussion of cases suspected to have GI lymphoma is of paramount importance. 425 TREATMENT APPROACH AND PROGNOSTIC FACTORS IN PATIENTS WITH PRIMARY GASTRIC DIFFUSE LARGE B CELL LYMPHOMA D. Antic,1 J. Jelicic,2 V. Djurasinovic,2 V. Vukovic,2 N. Milic,3 M. Todorovic,1 J. Bila,1 B. Andjelic,2 M. Perunicic Jovanovic,2 L. Jakovic,2 B. Mihaljevic.1 1Clinical Center Serbia, Clinic for Hematology, Medical Faculty, Belgrade University, Belgrade, Serbia and Montenegro, 2Clinical Center Serbia, Clinic for Hematology, Belgrade, Serbia and Montenegro, 3Institut for Medical Statistic and Informatic, Medical Faculty, Belgrade University, Belgrade, http://www.selleckchem.com/products/ABT-263.html Serbia and Montenegro Introduction: Primary gastric (PG) non Hodgkin lymphoma (NHL) is a malignancy localized in the stomach with or without abdominal and/or extraabdominal lymph nodal involvement and constitutes 20-30% of all extranodal NHLs. Any lymphoma category can arise in the stomach, but about 60% of cases are diffuse large B cell lymphoma (DLBCL). The most appropriate reliable staging system, prognostic factors and treatment protocols for PG-DLBCL remain unclear. Lack of strong recommendations may be due to the fact that studies have involved heterogeneous management without long follow up data. Therefore, we evaluated the efficacy of immunochemotherapy (Rituximab plus CHOP regimen), benefit of additional surgery http://www.selleck.cn/products/Erlotinib-Hydrochloride.html and also we tried to define the most important prognostic factors for overall survival (OS). Methods: We retrospectively analysed 73 patients with newly diagnosed primary gastric DLBCL treated with Rituximab plus CHOP regimen (R-CHOP) with or without surgery as the additional treatment. Results: Tumor resection did not improve 5-years OS (75,9% and 65,9%, for surgery plus immunochemotherapy and immunochemotherapy alone, respectively, p=0.293). Ann Arbor clinical stage ��II (p=0.047), ECOG performanse status ��2 (p=0.008), IPI��2 (p=0.038), trombocytosis �� 450x109/l (p=0.001), level of C reactive protein higher than �� 5mg/l (p=0.028) and hypoalbuminemia